Augmedix Announces Additional $19 Million in Series B Funding

Oct 24, 2019 | News, Press Releases

SAN FRANCISCO, Oct. 24, 2019 (PRNewswire) — Today, Augmedix announced that it has received $19 million in Series B funding that includes investments from Redmile Group, McKesson Ventures, DCM Ventures, Wanxiang Healthcare Investments and others.

The company will use this fresh funding to accelerate product development, including automation capabilities, and to strategically scale its technology-enabled service across health systems and private clinics nationwide.

“We have strong confidence in the Augmedix team’s ability to execute on its goal of reducing physician burnout and significantly improving their quality of life,” said Tom Rodgers, senior vice president and managing director at McKesson Ventures. “Augmedix is uniquely positioned to leverage trained medical documentation experts, increasingly enabled by artificial intelligence, to deliver a consumer-grade experience for the clinician that results in more accurate and timely documentation in the most cost-effective manner possible.”

“Augmedix has helped our efforts to enhance clinician-patient visits and to boost clinician productivity by maximizing our time together.”

Fifteen national health systems, including Sutter Health, CommonSpirit Health, and US Oncology, representing more than 10% of clinicians in the United States, have partnered with Augmedix. The company has over one thousand team members worldwide that are focused on developing and delivering the service.

“Augmedix has expanded our care teams in a novel way, supporting clinicians from primary care, to dermatology and gastroenterology,” said Albert Chan, M.D., M.S., chief of digital patient experience at Sutter Health. “Augmedix has helped our efforts to enhance clinician-patient visits and to boost clinician productivity by maximizing our time together.”

“We appreciate the confidence our investors have shown in Augmedix and are excited by how quickly the industry has adopted our service,” said Manny Krakaris, chief executive officer at Augmedix. “Our service is differentiated because it operates in real-time and is enabled by natural conversation, not burdensome single-party dictation. The combination of our proprietary technology and expert teams reliably delivers the highest quality medical notes thus relieving clinicians of that burden. We will continue to be at the forefront of medical documentation services by investing heavily in technology that will enable us to efficiently deliver additional services and features to our health system customers.”

Media Contact
Kaila Grafeman
Augmedix
pr@augmedix.com

About Augmedix, Inc.
Augmedix, Inc. (Nasdaq: AUGX) provides automated medical documentation and data services to large healthcare systems and physician practices, supporting medical offices, clinics, hospitals, emergency departments, and telemedicine nationwide. The Company’s Ambient Automation Platform converts the natural conversation between physicians and patients into timely and comprehensive medical notes and performs a suite of related data services. These services relieve physicians of administrative burdens to enable more time for patient care. Augmedix’s proprietary platform uses automatic speech recognition, natural language processing, and clinical datasets to capture the ambient visit conversation and generate a structured medical note. The structured medical note data is then used to deliver additional data services. Quality is assured by trained medical documentation specialists. To learn more about Augmedix, visit augmedix.com.